CURRENT SERIES:
Understanding Axial Spondyloarthritis
December 27, 2018
December 27, 2018
January 03, 2019
January 03, 2019
January 10, 2019
January 10, 2019
January 17, 2019
January 17, 2019
January 24, 2019
February 21, 2019
February 21, 2019
February 28, 2019
February 28, 2019
March 07, 2019
March 07, 2019
March 14, 2019
March 14, 2019
March 21, 2019
March 21, 2019
March 21, 2019
March 28, 2019
March 28, 2019
May 31, 2019
NOW PLAYING
The Future of Axial Spondyloarthritis Treatment
24 of 24
May 31, 2019

The Future of Axial Spondyloarthritis Treatment

Hillary Norton, MD, discusses the unmet needs in the treatment of axial spondyloarthritis and provides community rheumatologists with management advice.


Hillary Norton, MD: There are unmet needs yet in the treatment of axSpA [axial spondyloarthritis] and AS [ankylosing spondylitis] patients. TNF [tumor necrosis factor] inhibitors and IL-17 inhibitors work very well for many of our patients, but we still have cases in which if someone doesn’t respond to 1 of these biologics, the pipeline includes new classes of medications that are coming, and this will provide more options for these patients who don’t respond to the medications we currently have.

I think the main thing to keep in mind for community physicians who are seeing people with back pain is the distinction between mechanical and inflammatory back pain. If somebody comes in under the age of 35 with back pain that has been persistent for more than 3 months, who has night pain, particularly in the second half of the night, and pain that is better with activity and worse with rest, and is responsive to NSAIDs [nonsteroidal anti-inflammatory drugs], these are red flags that this may be treatable inflammatory back pain and a referral to rheumatology is warranted.
 
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up